Condition: Langerhans Cell Histiocytosis · Sponsor: Cook Children's Health Care System
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
This description comes directly from the study's public registry record.
Megan Gibbs, BSN, RN · (682) 885-2116 · megan.gibbs@cookchildrens.org
Angelica Gonzalez, PhD · (682) 3033120 · angelica.gonzalez@cookchildrens.org
Always discuss trial participation with your own doctor first.
| Cook Children's Health Care System | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06582745